New drug targets belly fat for weight loss
A clinical study confirmed that the experimental injection "CBL-514" helps reduce abdominal fat and visceral fat surrounding internal organs, which are linked to higher risks of heart disease and diabetes. The treatment, which directly targeted fat cells, showed a significant decrease in subcutaneous fat by up to 70% and about a 12% reduction in internal organ fat over three months, with mild side effects such as redness and pain at the injection site. Currently, Phase III studies are underway to confirm the safety and long-term efficacy of the drug, with expectations that it will contribute to improved health indicators related to obesity and visceral fat.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)